{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T03:28:35Z","timestamp":1784690915668,"version":"3.55.0"},"reference-count":34,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Campania Region and Novartis Gene Therapies"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJNS"],"abstract":"<jats:p>Spinal muscular atrophy (SMA) is a rare neuromuscular disorder causing progressive muscle weakness. Severe SMA forms are typically observed up to six months postnatally. Disease-modifying therapies provide significant benefits, making newborn screening (NBS) essential for timely diagnosis and treatment initiation. The NBS programme evaluated infants born between April 2023 and October 2024 in the Campania region, Italy. DNA was amplified to detect homozygous deletion of the SMN1 gene by RT-PCR and SMN2 copy number using multiplex ligation-dependent probe amplification. Following treatment, motor functions were assessed using CHOP-INTEND and Bayley III scales. Among 62,801 infants screened for SMA, thirteen (11 females, 2 males) tested positive. The distribution of SMN2 copy numbers was as follows: eight patients had two copies, one patient had three, and four patients had four copies. One year after treatment, motor outcome data were available for four of the eight patients with two SMN2 copies. Among these patients, one achieved the milestones of walking without support, and three were standing with support. At 24 months, three of these patients were walking independently. Pre-symptomatic treatment markedly improves motor function development. This underscores the urgent need for large-scale newborn screening to prevent diagnostic delays and ensure timely, effective therapy. Validated care protocols must be established to facilitate early diagnosis and intervention.<\/jats:p>","DOI":"10.3390\/ijns12010016","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T15:49:42Z","timestamp":1773071382000},"page":"16","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Experience of Timing Treatment in Newborns with Spinal Muscular Atrophy: A Call for Standardized Screening Practices in Italy"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3434-8668","authenticated-orcid":false,"given":"Ilaria","family":"Bitetti","sequence":"first","affiliation":[{"name":"Pediatric Neurology, Santobono-Pausilipon Children\u2019s Hospital, 80129 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Iannaccone","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Santobono-Pausilipon Children\u2019s Hospital, 80129 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Margiotta","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Santobono-Pausilipon Children\u2019s Hospital, 80129 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Varone","sequence":"additional","affiliation":[{"name":"Pediatric Neurology, Santobono-Pausilipon Children\u2019s Hospital, 80129 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41572-022-00380-8","article-title":"Spinal muscular atrophy","volume":"8","author":"Mercuri","year":"2022","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Nishio, H., Niba, E.T.E., Saito, T., Okamoto, K., Takeshima, Y., and Awano, H. (2023). Spinal Muscular Atrophy: The Past, Present, and Future of Diagnosis and Treatment. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241511939"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.2147\/DDDT.S214174","article-title":"Disease Modifying Therapies for the Management of Children with Spinal Muscular Atrophy (5q SMA): An Update on the Emerging Evidence","volume":"16","author":"Hjartarson","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrneurol.2018.4","article-title":"Advances in therapy for spinal muscular atrophy: Promises and challenges","volume":"14","author":"Groen","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1212\/WNL.0000000000201654","article-title":"Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey","volume":"100","author":"Coratti","year":"2023","journal-title":"Neurology"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Cooper, K., Nalbant, G., Sutton, A., Harnan, S., Thokala, P., Chilcott, J., McNeill, A., and Bessey, A. (2024). Systematic Review of Newborn Screening Programmes for Spinal Muscular Atrophy. Int. J. Neonatal Screen., 10.","DOI":"10.3390\/ijns10030049"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.nmd.2021.03.007","article-title":"Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go","volume":"31","author":"Dangouloff","year":"2021","journal-title":"Neuromuscul. Disord."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1136\/jmg-2022-108873","article-title":"Experience of a 2-year spinal muscular atrophy NBS pilot study in Italy: Towards specific guidelines and standard operating procedures for the molecular diagnosis","volume":"60","author":"Abiusi","year":"2023","journal-title":"J. Med. Genet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/acn3.52018","article-title":"Early spinal muscular atrophy treatment following newborn screening: A 20-month review of the first Italian regional experience","volume":"11","author":"Gagliardi","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1007\/s00431-022-04470-3","article-title":"Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening","volume":"181","author":"Pane","year":"2022","journal-title":"Eur. J. Pediatr."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e200310","DOI":"10.1212\/CPJ.0000000000200310","article-title":"Spinal Muscular Atrophy Update in Best Practices: Recommendations for Diagnosis Considerations","volume":"14","author":"Schroth","year":"2024","journal-title":"Neurol. Clin. Pract."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s40263-022-00910-8","article-title":"Risdiplam: A Review in Spinal Muscular Atrophy","volume":"36","author":"Paik","year":"2022","journal-title":"CNS Drugs"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Cooper, K., Nalbant, G., Sutton, A., Harnan, S., Thokala, P., Chilcott, J., McNeill, A., and Bessey, A. (2024). Systematic Review of Presymptomatic Treatment for Spinal Muscular Atrophy. Int. J. Neonatal Screen., 10.","DOI":"10.3390\/ijns10030056"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1001\/jamapediatrics.2024.0492","article-title":"Clinical Effectiveness of Newborn Screening for Spinal Muscular Atrophy: A Nonrandomized Controlled Trial","volume":"178","author":"Schwartz","year":"2024","journal-title":"JAMA Pediatr."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3233\/JND-230122","article-title":"Real-World Outcomes in Patients with Spinal Muscular Atrophy Treated with Onasemnogene Abeparvovec Monotherapy: Findings from the RESTORE Registry","volume":"11","author":"Servais","year":"2024","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"17562864231154335","DOI":"10.1177\/17562864231154335","article-title":"Longitudinal developmental profile of newborns and toddlers treated for spinal muscular atrophy","volume":"16","author":"Ngawa","year":"2023","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Qiao, Y., Chi, Y., Gu, J., and Ma, Y. (2023). Safety and Efficacy of Nusinersen and Risdiplam for Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Brain Sci., 13.","DOI":"10.3390\/brainsci13101419"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejpn.2024.05.002","article-title":"Cognitive function in SMA patients with 2 or 3 SMN2 copies treated with SMN-modifying or gene addition therapy during the first year of life","volume":"51","author":"Steffens","year":"2024","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Zaidman, C.M., Crockett, C.D., Wedge, E., Tabatabai, G., and Goedeker, N. (2024). Newborn Screening for Spinal Muscular Atrophy: Variations in Practice and Early Management of Infants with Spinal Muscular Atrophy in the United States. Int. J. Neonatal Screen., 10.","DOI":"10.3390\/ijns10030058"},{"key":"ref_20","unstructured":"Rare, O.M. (2025, October 13). Screening Neonatale per la SMA in Campania: La Prospettiva del CEINGE. Available online: https:\/\/www.osservatoriomalattierare.it\/malattie-rare\/sma-atrofia-muscolare-spinale\/21934-screening-neonatale-per-la-sma-in-campania-la-prospettiva-del-ceinge."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/pr.2014.10","article-title":"Using the Bayley-III to assess neurodevelopmental delay: Which cut-off should be used?","volume":"75","author":"Johnson","year":"2014","journal-title":"Pediatr. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/j.ymthe.2024.06.020","article-title":"Clinical perspectives: Treating spinal muscular atrophy","volume":"32","author":"McPheron","year":"2024","journal-title":"Mol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: The Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1007\/s12325-024-02845-6","article-title":"Long-Term Comparative Efficacy and Safety of Risdiplam and Nusinersen in Children with Type 1 Spinal Muscular Atrophy","volume":"41","author":"Kokaliaris","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejpn.2024.06.004","article-title":"An updated systematic review on spinal muscular atrophy patients treated with nusinersen, onasemnogene abeparvovec (at least 24 months), risdiplam (at least 12 months) or combination therapies","volume":"51","author":"Giess","year":"2024","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/21678707.2022.2152671","article-title":"Risdiplam as an orphan drug treatment of spinal muscular atrophy in adults and children (2 months or older)","volume":"10","author":"Deconinck","year":"2022","journal-title":"Expert Opin. Orphan Drugs"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1212\/WNL.0000000000205694","article-title":"RAINBOWFISH: Primary Efficacy and Safety Data in Risdiplam-treated Infants with Presymptomatic Spinal Muscular Atrophy (SMA) (S37.006)","volume":"102","author":"Servais","year":"2024","journal-title":"Neurology"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Dosi, C., and Masson, R. (2024). The impact of three SMN2 gene copies on clinical characteristics and effect of disease-modifying treatment in patients with spinal muscular atrophy: A systematic literature review. Front. Neurol., 15.","DOI":"10.3389\/fneur.2024.1308296"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/dmcn.15286","article-title":"Financial cost and quality of life of patients with spinal muscular at rophy identified by symptoms or newborn screening","volume":"65","author":"Dangouloff","year":"2023","journal-title":"Dev. Med. Child Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.3390\/ijns7030033","article-title":"Landscape of spinal muscular atrophy newborn screening in the United States: 2018\u20132021","volume":"7","author":"Hale","year":"2021","journal-title":"Int. J. Neonatal Screen."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Varone, A., Esposito, G., and Bitetti, I. (2025). Spinal muscular atrophy in the era of newborn screening: How the classification could change. Front. Neurol., 16.","DOI":"10.3389\/fneur.2025.1542396"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S2352-4642(22)00342-X","article-title":"Newborn screening for spinal muscular atrophy in Australia: A non-rand omised cohort study","volume":"7","author":"Kariyawasam","year":"2023","journal-title":"Lancet Child Adolesc. Health"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/dmcn.15117","article-title":"Integrating newborn screening for spinal muscular atrophy into health care systems: An Australian pilot programme","volume":"64","author":"Kariyawasam","year":"2022","journal-title":"Dev. Med. Child Neurol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"7S45","DOI":"10.1016\/S0929-693X(20)30277-3","article-title":"Multidisciplinary approach and psychosocial management of spinal muscular atrophy (SMA)","volume":"27","author":"Ropars","year":"2020","journal-title":"Arch. Pediatr."}],"container-title":["International Journal of Neonatal Screening"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2409-515X\/12\/1\/16\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T09:51:12Z","timestamp":1773222672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2409-515X\/12\/1\/16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["ijns12010016"],"URL":"https:\/\/doi.org\/10.3390\/ijns12010016","relation":{},"ISSN":["2409-515X"],"issn-type":[{"value":"2409-515X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]}}}